Pazopanib Hydrochloride CAS 635702-64-6 Kuchena >99.0% (HPLC) API Factory

Tsanangudzo Pfupi

Kemikari Zita: Pazopanib Hydrochloride

CAS: 635702-64-6

Chitarisiko: Muchena kusvika kuYellow Powder

Kuchena:> 99.0% (HPLC)

Tyrosine kinase receptor inhibitor yekurapa advanced renal cell carcinoma kana advanced soft tissue sarcoma.

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Tumira email kwatiri

Product Detail

Product Tags

Tsanangudzo:

Mugadziri Wekutengesa ane Kuchena Kwepamusoro uye Hunhu Hwakagadzikana
Kemikari Zita: Pazopanib Hydrochloride
CAS: 635702-64-6
Tyrosine kinase receptor inhibitor yekurapa advanced renal cell carcinoma kana advanced soft tissue sarcoma avo vakambogamuchira chemotherapy.
API High Quality, Commercial Production

Chemical Properties:

Chemical Name	Pazopanib Hydrochloride
Mashoko anoreva zvakafanana	Pazopanib HCl;GW786034 HCl;Votrient;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride
Nhamba yeCAS	635702-64-6
Nhamba yeCAT	RF-API93
Stock Status	MuStock, Kugadzirwa Kunokwira Kusvika Mazana emaKilogram
Molecular Formula	C21H23N7O2S.ClH
Molecular Weight	473.987
Solubility	DMSO
Melting Point	300.0~304.0℃
Brand	Ruifu Chemical

Zvinotsanangurwa:

Item	Zvinotsanangurwa
Chitarisiko	Hupfu hwakachena kusvika kuYellow
Identification	Iyo infraed absorption spectrum yemuyedzo sampuli inopindirana neiyo chiyero
Residue paIgnition	≤0.50%
Chero Kusachena Kwemunhu	≤0.30%
Zvose Zvisina Kuchena	≤1.50%
Heavy Metals	≤10ppm
Kuchena / Analysis Method	≥99.0% (HPLC)
Test Standard	Enterprise Standard
Usage	API, Tyrosine kinase receptor inhibitor

Package & Kuchengeta:

Package: Bhodhoro, Aluminium foil bag, Cardboard dhiramu, 25kg/Drum, kana zvinoenderana nezvinodiwa nemutengi.

Storage Condition:Chengetedza mumidziyo yakavharwa panzvimbo inotonhorera uye yakaoma;Dzivirira kubva kuchiedza, mwando uye tumbuyu.

Zvakanakira:

FAQ:

Application:

Pazopanib Hydrochloride (CAS 635702-64-6) inonzi multi-tyrosine kinase inhibitor yevascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR) -α uye - β, fibroblast kukura factor receptor (FGFR) -1 uye -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), uye transmembrane glycoprotein receptor tyrosine kinase (cFms).In vitro, pazopanib inhibited ligand-induced autophosphorylation yeVEGFR-2, Kit, uye PDGFR-beta receptors.In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation mumbeva mapapu, angiogenesis mune mbeva modhi, uye kukura kweimwe bundu remunhu xenografts mumakonzo.Yakatenderwa renal cell carcinoma neUS Food and Drug Administration muna 2009 uye inotengeswa pasi pezita rekutengeserana Votrient nemugadziri wemushonga, GlaxoSmithKline.Votrient is kinase inhibitor inoratidzwa pakurapa varwere vane: 1) advanced renal cell carcinoma.2) advanced soft tissue sarcoma avo vakambogamuchira chemotherapy.